RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, In c. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announces the first patient was dosed at ...
Convergent Therapeutics' Dr. Philip Kantoff and Plus Therapeutics' Dr. Marc Hedrick discuss how unmet medical needs, maturing ...
[212 Pb]VMT-α-NET shows promise in effectively treating neuroendocrine tumors Administration of fractionated doses of [212 Pb]VMT-α-NET shows 100% survival in a robust model of metastatic ...
A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, ...
BERLIN--(BUSINESS WIRE)-- Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary ...
Perspective Therapeutics, Inc. announced that updated data from its [212Pb]VMT-α-NET program will be presented at the ESMO Congress 2025 in Berlin from October 17 to 21, 2025. The presentation will, ...
Researchers gain new insights into how the isotope astatine-211 interacts with resins commonly used to purify the isotope for therapeutic use Targeted Alpha Therapy (TAT) is one of the most powerful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results